What is Vesalio?
Founded in 2013, Vesalio operates at the intersection of medical engineering and acute stroke care. The company is best known for its proprietary NeVa platform, a sophisticated neurovascular device engineered to address the complexities of acute ischemic stroke. By focusing on first-pass recanalization, Vesalio provides physicians with the tools necessary to remove diverse clot morphologies, thereby improving patient outcomes in high-stakes clinical environments. The company's market position is defined by its technical differentiation in vascular occlusion, moving beyond traditional mechanical thrombectomy limitations to offer a more reliable, comprehensive solution for neuro-interventionalists.
How much funding has Vesalio raised?
Vesalio has raised a total of $5M across 1 funding round:
Other Financing Round
$5M
Other Financing Round (2019): $5M, investors not publicly disclosed
Key Investors in Vesalio
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Vesalio?
With the recent infusion of capital, Vesalio is positioned to transition into a more aggressive phase of commercial expansion and clinical validation. The strategic roadmap likely involves scaling the manufacturing of the NeVa platform to meet increasing global demand while simultaneously investing in clinical trials to further solidify its evidence-based market position. As the company navigates this major enterprise-level funding stage, the focus will remain on enhancing its intellectual property portfolio and expanding its footprint in key international markets. By leveraging this financial backing, Vesalio aims to set a new standard for efficacy in neurovascular intervention, ensuring that its technology remains at the forefront of stroke care innovation.
See full Vesalio company page
